Clinical trial
Treatment of Executive Dysfunction in Parkinson's Disease
NCT00286949 · Johns Hopkins University, Other · Completed
Key facts
| NCT number | NCT00286949 |
|---|---|
| Title | Treatment of Executive Dysfunction in Parkinson's Disease |
| Official title | Atomoxetine for the Treatment of Executive Dysfunction in Patients With Parkinson's Disease: A Pilot Open-label Study |
| Lead sponsor | Johns Hopkins University, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | Atomoxetine |
| Enrollment | 12 |
| Start date | Jan 6, 2005 |
| Primary completion | Jun 30, 2008 |
| Completion | Jun 30, 2008 |
| First posted | Feb 6, 2006 |
| Last update posted | Nov 6, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: